ライフサイエンスコーパス: cGMP

1 cGMP also decreased cAMP levels and PKA activity in dise

2 cGMP binding to PKG Ialpha attenuates oxidant-induced di

3 cGMP-AMP (cGAMP) synthase (cGAS) is a cytosolic DNA sens

4 cGMP-AMP synthase (cGAS) is a key DNA sensor that produc

5 cGMP-AMP synthase, ritinoic acid-inducible protein 1 (RI

6 cGMP/cGKII rapidly inhibited NHE3, which was associated

7 We conclude that 1) cGMP inhibition of NHE3 is associated with phosphorylati

8 dy, we tested the ability of cGMP and type 2 cGMP-dependent protein kinase (PKG2) to activate forkhea

9 3) cGMP- and Ca(2+)-mediated inhibition of NHE3 was impaire

10 ast lines were established under ISO class 5 cGMP conditions.

11 and FoxO target genes were unaffected by 8Br-cGMP challenge in vitro.

12 t of human colonic biopsy specimens with 8Br-cGMP also activated catalase and manganese superoxide di

13 Treatment of colon explants with 8Br-cGMP also activated FoxO target gene expression at both

14 nafil were abolished by PKG inhibitor Rp-8Br-cGMPs.

15 NPRA) receptor and, in turn, by activating a cGMP-dependent pathway.

16 urons: High CO2 tonically activates AWC by a cGMP-dependent mechanism, and AWC output inhibits the HS

17 nsulin secretion, which could be caused by a cGMP-mediated inhibition of PDE3B, which in turn reduces

18 ulata, a model system of sperm chemotaxis, a cGMP signaling pathway controls these Ca(2+) bursts.

19 ans, the AWC neurons are thought to deploy a cGMP signaling cascade in the detection of and response

20 oposed, in which PKGIalpha is activated in a cGMP-independent fashion via oxidation of Cys(43), resul

21 NO also appears to function in a cGMP-independent manner, via S-nitrosation (SNO), a redo

22 c4- mediated TRPC6 expression in PASMCs in a cGMP-PKG-dependent manner.

23 duction of full-length PfRH5 protein using a cGMP-compliant platform called ExpreS(2), based on a Dro

24 tion or environmental acidification, while a cGMP-phosphodiesterase inhibitor circumvents egress repr

25 Defects in the BNP/GC-A/cGMP pathway may play a role in arteriopathies in women,

26 ity effects of paracrine endothelial NP/GC-A/cGMP signaling and facilitate neutrophil extravasation d

27 However, NP/GC-A/cGMP signaling protects podocyte integrity under patholo

28 sis factor-alpha-induced endothelial NP/GC-A/cGMP/PDE2 signaling impairs endothelial barrier function

29 ce of CNG channel alone also caused abnormal cGMP accumulation.

30 occurs in early cardiac hypertrophy, affects cGMP-mediated contractility, and might represent a previ

31 tween Cys117 and Cys195 in the high affinity cGMP-binding site.

32 ion of cGKI, induction of PDE2A, and altered cGMP/cAMP cross talk.

33 Although cGMP signaling is necessary for thermotransduction, the

34 gh previous studies indicate that Ca(2+) and cGMP control microneme secretion, little is known about

35 results in elevation of cytosolic Ca(2+) and cGMP.

36 strategy within routine, high-activity, and cGMP productions attests to its practicality and reliabi

37 eling within a one-step, fully automated and cGMP compliant radiosynthesis of [(18)F]UCB-H ([(18)F]7)

38 express RXFP1, ML290 increased both cAMP and cGMP accumulation but not p-ERK1/2.

39 enzyme that catalyzes hydrolysis of cAMP and cGMP and is highly expressed in tissues that regulate en

40 Elevation of both cAMP and cGMP by PDE10 inhibition was required for rescue.

41 f dystonia, PDE10A, a key enzyme in cAMP and cGMP catabolism, is downregulated in striatal projection

42 key role limiting the hydrolysis of cAMP and cGMP in disease, and as a consequence this influences th

43 es assessed the respective roles of cAMP and cGMP in the above effects using soluble guanylyl cyclase

44 Testing a panel of modulators of cAMP and cGMP signaling pathways, FASS-LTP identified vardenafil

45 critical role in the regulation of cAMP and cGMP signaling.

46 sis suggested the interplay between cAMP and cGMP signalling as PKAc1 inactivation changes the phosph

47 l substrate enzyme, which regulates cAMP and cGMP signalling cascades, thus having a key role in the

48 showed that PDE11A, which degrades cAMP and cGMP, is preferentially expressed in CA1 and subiculum o

49 the catabolism of second messenger cAMP and cGMP, whose synthesis is stimulated by D1 receptors and

50 eotide (cGMP)-activated Ca(2+) channels, and cGMP have been linked to signaling downstream of recepto

51 activation of the NPR2 guanylyl cyclase, and cGMP hydrolysis is increased by activation of the PDE5 p

52 2 (PDE2), a medium spiny neuron-enriched and cGMP-activated PDE, in AMPAR trafficking.

53 feron gamma-inducible protein 16 (IFI16) and cGMP-AMP synthase (cGAS) have both been proposed to dete

54 tivation of purified sGC in VSMC lysates and cGMP accumulation in intact porcine aortic endothelial c

55 Formation of NO and cGMP accumulation were inhibited by ALDH inhibitors chlo

56 rming guanylyl cyclase-A (GC-A) receptor and cGMP-dependent kinase I (cGKI), strengthen systemic endo

57 pig jejunal tissue, and fluid retention and cGMP levels in STa-exposed loops.

58 ation of soluble guanylate cyclase (sGC) and cGMP-mediated vasodilation.

59 dation of sGC, NO dissociation from sGC, and cGMP degradation by PDE, exerted a dominant influence on

60 ivity-related musclin-dependent boost of ANP/cGMP signaling results in significantly lower maximum ae

61 Then, within 1 min of LH application, cGMP begins to decrease in the peripheral granulosa cell

62 f human therapeutic proteins in FDA-approved cGMP facilities, development of tags to deliver protein

63 on in PKGIalpha, inducing the same effect as cGMP binding, namely kinase activation and thus vasorela

64 I IFN production, and STING agonists such as cGMP-AMP (cGAMP) and other cyclic dinucleotides elicit p

65 Basal cGMP level is strictly controlled by the opposing action

66 fluorescence resonance energy transfer-based cGMP biosensor cGi500, NO-induced elevation of cGMP was

67 Because cGMP plays a key role in these processes, here we invest

68 lic nucleotide-binding domain B of PKG binds cGMP with higher affinity than cAMP, the intracellular c

69 a dual substrate PDE that can hydrolyze both cGMP and cAMP.

70 oxide(NO) donor), PITO (NO scavenger), 8-Br-cGMP (cGMP analog).

71 3',5'-cyclic monophosphate sodium salt (8-Br-cGMP), or pioglitazone dose-dependently downregulated po

72 counteracted effects of sildenafil and 8-Br-cGMP.

73 ns affect the regulation of SERT activity by cGMP-dependent phosphorylation.

74 in normal neurons that were not affected by cGMP.

75 ts as a nonselective cation channel gated by cGMP, a property shown previously to facilitate rapid ce

76 ions, a nonselective cation channel gated by cGMP.

77 has the unique property to be stimulated by cGMP, but primarily hydrolyzes cAMP.

78 has the unique property to be stimulated by cGMP, but primarily hydrolyzes cAMP.

79 +) channels of the BK type are stimulated by cGMP/cGMP-dependent protein kinase type I, and recent ex

80 effect of erlotinib was independent of cAMP, cGMP, and protein kinase A.

81 ctrophysiology experiments showed that cAMP, cGMP, and cCMP were effective agonists of the channel an

82 PDE10A hydrolyses cAMP/cGMP signalling cascades, thus having a key role in the

83 Changes in cAMP/cGMP levels, PKA/PKG and BDNF expression were also preve

84 ly expressing D2 receptors that inhibit cAMP/cGMP synthesis.

85 intensity and duration of D2-inhibited cAMP/cGMP signaling.SIGNIFICANCE STATEMENT In DYT1 transgenic

86 ively of D1-stimulated and D2-inhibited cAMP/cGMP signals.

87 expressing D1 receptors that stimulate cAMP/cGMP synthesis.

88 intensity and duration of D1-stimulated cAMP/cGMP signaling; conversely, the increase of PDE10A in th

89 nitive performance in AD are related to cAMP/cGMP-dependent pathways.

90 AtPNP-A also causes cGMP-dependent net water uptake into WT protoplasts, and

91 o known as Npr2 or NPR-B), increase cellular cGMP and cause skeletal overgrowth, but how these mutati

92 Moreover, cGK (cGMP-dependent protein kinase) activity was downregulate

93 ed synthesis of cGMP and activation of cGK1 (cGMP-dependent protein kinase 1) in cultured porcine val

94 exchanger NHE3 is acutely inhibited by cGKII/cGMP, but how cGKII inhibits NHE3 is unknown.

95 (NO) donor), PITO (NO scavenger), 8-Br-cGMP (cGMP analog).

96 sma membrane and generates compartmentalized cGMP in gut epithelia in UC.

97 As a consequence, cGMP from the oocyte diffuses into the sink provided by

98 hoprotein was increased in response to 8-CPT-cGMP treatment, but not when disulfide formation in PKGI

99 The nitric oxide-sensitive guanylyl cyclase/cGMP-dependent protein kinase type I signaling pathway c

100 Activation of the D1R/cGMP/PKG pathway induces apoptosis in vitro and causes t

101 in outer granulosa cells to rapidly decrease cGMP.

102 their tissue-specific expression, different cGMP affinities, and isoform-specific protein-protein in

103 sensor that produces the cyclic dinucleotide cGMP-AMP (cGAMP) upon activation, which binds to and act

104 s (GCs), and mutations in genes that disrupt cGMP homeostasis leads to retinal degeneration in humans

105 Our data strongly implicate two distinct cGMP-mediated cell death pathways, and suggest that ther

106 ed by pharmacological therapies that elevate cGMP, which binds kinase to limit its oxidation.

107 els prolongs rod survival caused by elevated cGMP in a PDE6 mutant mouse model.

108 photoreceptor cell death caused by elevated cGMP.

109 es the pathological consequences of elevated cGMP and Ca2+, which are induced by the Pde6 mutation.

110 a phosphodiesterase inhibitor that elevated cGMP and separately increased Ca(2+) in a protein kinase

111 Because PDE5 inhibition elevates cGMP and protects from doxorubicin-induced injury, we re

112 Elevating cGMP restored the SHR Ca(2+) current to levels seen in n

113 ver, this pathway is regulated by endogenous cGMP/PKG2 signaling, and can be targeted using phosphodi

114 e endothelial expression of cGKI and enhance cGMP-stimulated phosphodiesterase 2A (PDE2A) levels.

115 Enhancing cGMP synthesis or blocking its degradation by phosphodie

116 erved ejection fraction (HFpEF) by enhancing cGMP signaling and improving hemodynamics, but real-worl

117 Here we address this issue for the essential cGMP-dependent protein kinase, PfPKG.

118 These receptor designs facilitate cGMP manufacturing of pure populations of engineered T c

119 he C43S-mutant PKGIalpha has a higher Ka for cGMP.

120 and Ser(663), all of which are necessary for cGMP/cGKII to inhibit NHE3.

121 ascular cells, ML290 was 10x more potent for cGMP accumulation and p-p38MAPK than for cAMP accumulati

122 ological evidence supported a switching from cGMP acting via PDE3 in control neurons to PDE2A in SHR

123 prevented in a genotype lacking a functional cGMP-activated Ca(2+) channel.

124 It is known that CodY consists of a GAF (cGMP-stimulated phosphodiesterases, adenylate cyclases,

125 established the central role of cyclic GMP (cGMP) from the granulosa cells in maintaining meiotic ar

126 Cyclic GMP (cGMP) generated in the granulosa cells diffuses through

127 e stable assembly of the retinal cyclic GMP (cGMP) phosphodiesterase (PDE6) holoenzyme.

128 ETEC-induced diarrhea, including cyclic GMP (cGMP) produced by GUCY2C, activation of cGMP-dependent p

129 rain axis that activates hypothalamic GUCY2C-cGMP signaling mediating satiety opposing obesity.

130 ie-induced guanylin loss silences the GUCY2C-cGMP paracrine axis underlying obesity-induced epithelia

131 High cGMP mediates the effects of glial KCC-3 on AFD shape by

132 compartmentalization of its closest homolog, cGMP-dependent protein kinase (PKG), via its own PKG anc

133 The type I cGMP-dependent protein kinases (PKGs) are key regulators

134 The decrease in cGMP in the oocyte relieves the inhibition of the meioti

135 itric oxide (NO) levels cause an increase in cGMP levels, so that cGMP inhibition of calcium influx c

136 e physiological (submicromolar) increases in cGMP concentration in an activity-dependent manner.

137 This reduction in cGMP affinity may in part explain the PKGIalpha loss-of-

138 ylyl cyclase-coupled receptors, resulting in cGMP generation.

139 tionally, this led to a significant shift in cGMP/cAMP cross-talk and, in particular, to cGMP-driven

140 of the hybrids and their ability to increase cGMP were estimated in vitro.

141 Only formoterol increased cGMP.

142 In HCFs, ML290 increased cGMP accumulation but did not affect p-ERK1/2 and given

143 endent manner that correlated with increased cGMP levels.

144 nhibitors have been successful at increasing cGMP levels in both cardiac and vascular tissues.

145 stress, is the best approach for increasing cGMP levels as compared with perturbation of other poten

146 hermore, we provide evidence that increasing cGMP rescues the channel phenotype and restores ion chan

147 hormones guanylin and uroguanylin, inducing cGMP signaling in colorectum and small intestine, respec

148 s), nitric oxide synthase, and intracellular cGMP, exerts a tonic enhancement of Ih selectively in py

149 s intracellular signaling pathways involving cGMP.

150 PDE10A operates downstream of nNOS to limit cGMP production and excitatory corticostriatal transmiss

151 e (Fe(3+)), is desensitized to NO and limits cGMP production needed for downstream activation of prot

152 ate cyclase-activating proteins (GCAPs) link cGMP synthesis to the light-induced fall in [Ca(2+)]i to

153 Nitrite dose-dependently increased local cGMP production at the dose of 2.6 mumol/min by 1.1 pmol

154 REEP6 plays an essential role in maintaining cGMP homeostasis though facilitating the stability and/o

155 The current model is that PKG, a malarial cGMP-dependent protein kinase, triggers egress, activati

156 alue of approximately 0.2 microM and maximal cGMP formation at 10 microM.

157 Because the second messenger cGMP exerts a central role in LTP mechanisms, here we st

158 ds bind GCs, generating the second messenger cGMP, which in turn leads to a variety of biological act

159 s signalling through two second-messengers - cGMP mediated by the parasite's cGMP-dependent protein k

160 stigate whether the intradisulfide modulates cGMP binding, real-time imaging was performed in vascula

161 ap assay, we demonstrate that Trx1 modulates cGMP synthesis through an association between Trx1 and G

162 nduced cyclic guanosine 3',5'-monophosphate (cGMP) production were selected by performing cyclase ass

163 (NO )-cyclic guanosine 3', 5'-monophosphate (cGMP) signaling has been observed in many cardiovascular

164 al via guanosine 3',5'-cyclic monophosphate (cGMP) and systemically affect plant salt and water balan

165 lished guanosine 3',5'-cyclic monophosphate (cGMP)-mediated signaling and inhibited platelet aggregat

166 e (NO)/guanosine 3',5'-cyclic monophosphate (cGMP)/protein kinase G (PKG) pathway.

167 ne-permeable cyclic guanosine monophosphate (cGMP) analog on KATP channel activity and insulin secret

168 er levels of cyclic guanosine monophosphate (cGMP) and peroxisome proliferator-activated receptor gam

169 eceptors and cyclic guanosine monophosphate (cGMP) are implicated in the response to sexual cues, whi

170 e (cAMP) and cyclic guanosine monophosphate (cGMP) are now recognized as important intracellular sign

171 Cyclic guanosine monophosphate (cGMP) is a second messenger molecule that transduces nit

172 r nucleotide cyclic guanosine monophosphate (cGMP) is found in many human organ tissues.

173 ) hydrolyzes cyclic guanosine monophosphate (cGMP) leading to increased levels of the cAMP response e

174 The cyclic guanosine monophosphate (cGMP) specific phosphodiesterase type 5 (PDE5) plays an

175 tor molecule cyclic guanosine monophosphate (cGMP), has been implicated in the progression of DN.

176 nafil in the cyclic guanosine monophosphate (cGMP)-activated protein kinase G (PKG) axis.

177 egans in the cyclic guanosine monophosphate (cGMP)-bound open state.

178 #3 relies on cyclic guanosine monophosphate (cGMP)-gated channels and activity of the ASJ, AWB, and A

179 synthesizes cyclic guanosine monophosphate (cGMP).

180 e (cAMP) and cyclic guanosine monophosphate (cGMP).

181 the cell by cyclic guanosine monophosphate (cGMP).

182 perturbation of the oxidatively-impaired NO -cGMP signaling pathway is a better approach to the resto

183 evidence point to impaired nitric oxide (NO)-cGMP bioavailability as playing a central role in each o

184 apies, an alternative strategy to restore NO-cGMP signaling is via inorganic nitrite.

185 pericytes and brain slices via inhibiting NO/cGMP pathway.

186 er SAH possibly by hemoglobin suppressing NO/cGMP signaling pathway.

187 mulation and p38MAPK phosphorylation but not cGMP accumulation or ERK1/2 phosphorylation although pri

188 fer biosensor revealed that PDE2 mediates NP/cGMP-driven decreases of submembrane cAMP levels.

189 e investigated whether the cyclic nucleotide cGMP influences Abeta levels and function during LTP and

190 osolic Ca(2+) elevations, cyclic nucleotide (cGMP)-activated Ca(2+) channels, and cGMP have been link

191 In this study, we tested the ability of cGMP and type 2 cGMP-dependent protein kinase (PKG2) to

192 GMP (cGMP) produced by GUCY2C, activation of cGMP-dependent protein kinase (PKG), and opening of the

193 motility through intercellular activation of cGMP-dependent protein kinase 1 (PKG1) signaling in glia

194 mic domain of BRI1 generates pmol amounts of cGMP per mug protein with a preference for magnesium ove

195 oy this approach to show that the binding of cGMP to pacemaking ion channels is weakened by a slower

196 There are several enzymatic determinants of cGMP levels in this pathway, including soluble guanylyl

197 , whether the molecular events downstream of cGMP involve BK channels present in cardiomyocytes or in

198 We also presented a remarkable elevation of cGMP and an increased activity of the cGMP-dependent pro

199 1 (PKG1), and was prevented by elevation of cGMP levels with the phosphodiesterase type 5 inhibitor

200 MP biosensor cGi500, NO-induced elevation of cGMP was detected in real-time in IHCs but not in OHCs.

201 cells expressing a dominant-negative form of cGMP-dependent protein kinase 1 (PKG1), and was prevente

202 herefore, agents enhancing the generation of cGMP for the treatment of these conditions have been int

203 We demonstrate that the increase of cGMP levels by the phosphodiesterase-5 inhibitors silden

204 ime- and concentration-dependent increase of cGMP levels.

205 similar to those elicited by an increase of cGMP, suggesting that intradisulfide formation is associ

206 show that AtPNP-A causes rapid increases of cGMP levels in wild type (WT) leaf tissue while this res

207 in rod outer segments reduced inhibition of cGMP production in the transgenic mouse retinas at the f

208 receptor ligands) maintain the low level of cGMP in the oocyte.

209 platelet hyperactivity through modulation of cGMP signaling.

210 y physiological events through production of cGMP from its receptor, the NO-sensitive guanylyl cyclas

211 We found that cGAS shows low production of cGMP-AMP in infected cells, but instead cGAS is partiall

212 Redistribution of cGMP-regulated phosphodiesterases and functional reorgan

213 s brought about by spatial redistribution of cGMP-sensitive phosphodiesterases 2 and 3 between both r

214 le cells, serving as a critical regulator of cGMP production and protein kinase G-dependent signaling

215 pH and PKAc1 act as balancing regulators of cGMP metabolism to control egress.

216 y is a better approach to the restoration of cGMP levels as compared with corresponding individual pe

217 We examined the role of cGMP phosphodiesterase (PDE6) in this difference by expr

218 Our findings demonstrate a role of cGMP/PKG signaling in ER stress and ER Ca(2+) channel re

219 (+/-) valves, and CNP triggered synthesis of cGMP and activation of cGK1 (cGMP-dependent protein kina

220 to examine two distinct cellular targets of cGMP: the cGMP-gated (CNG) channels and protein kinase G

221 s of cAMP are typically higher than those of cGMP, suggesting that the cGMP-versus-cAMP selectivity o

222 1 acts in the PSK signal pathway upstream of cGMP.

223 ee reaction steps had the greatest impact on cGMP accumulation.

224 tion by PDE, exerted a dominant influence on cGMP accumulation relative to other reaction steps.

225 heoretical effects of these interventions on cGMP levels.

226 signalling and brain natriuretic peptide on cGMP and cAMP regulation of cardiac sympatho-vagal trans

227 ll layers away from the oocyte lowers oocyte cGMP and restarts meiosis.

228 ctional BRI1 kinase is essential for optimal cGMP generation.

229 itors increase the intracellular cAMP and/or cGMP activities, which may ameliorate cognitive deficits

230 eomics approach based on immobilized cAMP or cGMP.

231 lase (sGC), a key enzyme in the nitric oxide/cGMP signaling pathway.

232 This occurs by two complementary pathways: cGMP production is decreased by dephosphorylation and in

233 inase of AGC family (the cAMP-dependent PKA, cGMP- dependent protein kinase G and phospholipid-depend

234 nt with current Good Manufacturing Practice (cGMP).

235 ost of current Good Manufacturing Practices (cGMP) production.

236 cursor cells from adult skin in a non-profit cGMP environment.

237 es the phosphorylation profile of a putative cGMP-phosphodiesterase.

238 nd downstream signaling, namely the putative cGMP and Ca(2+) pathways, ion-channel activity modulatio

239 ease in the granulosa cells results in rapid cGMP diffusion out of the oocyte, initiating meiotic res

240 which the Ca(2+) sensitivity of the retinal cGMP production was affected.

241 The Cngb1 locus-encoded beta-subunit of rod cGMP-gated cation channel and associated glutamic acid r

242 interaction with HSP90 and modulate the rod cGMP PDE6 stability and activity.

243 messengers - cGMP mediated by the parasite's cGMP-dependent protein kinase (PKG), and Ca(2+) , mediat

244 e findings identify new insights into NO-sGC-cGMP signaling and reveal cytochrome b5 reductase 3 as t

245 cursor cells were generated using a stepwise cGMP-compliant 3D differentiation protocol.

246 n and activity is critical for NO-stimulated cGMP production and vasodilation.

247 he surface of cells but failed to synthesize cGMP in membrane GC assays.

248 Recombinant ROS-GCs synthesized cGMP from GTP at faster rates in the presence of bicarbo

249 novel drugs directly or indirectly targeting cGMP as well as the progress of research to date.

250 lcium channels in the SHR and that targeting cGMP can restore the channel phenotype.

251 ow using Arabidopsis root cell cultures that cGMP rapidly potentiates phosphorylation of the downstre

252 This study tested the hypothesis that cGMP inhibits NHE3 by phosphorylating it and altering it

253 We show that cGMP enhances Abeta production by increasing the APP/BAC

254 Here we show that cGMP-selective PDE9A is expressed in the mammalian heart

255 ls cause an increase in cGMP levels, so that cGMP inhibition of calcium influx can limit NO productio

256 Taken together, our results suggest that cGMP acts as a modulator that enhances downstream signal

257 Our data suggest that cGMP positively regulates Abeta levels in the healthy br

258 re still responsive to cGMP, suggesting that cGMP acts downstream of PSKR1.

259 The cGMP decrease in the granulosa cells results in rapid cG

260 The cGMP-dependent protein kinase-1alpha (PKG1alpha) transdu

261 e two distinct cellular targets of cGMP: the cGMP-gated (CNG) channels and protein kinase G (PRKG), a

262 s expressing a FRET-biosensor comprising the cGMP-binding sites of PKGIalpha.

263 eclinical studies suggest that elevating the cGMP intracellular pool through inhibition of the cGMP-h

264 tes the real value of iodonium salts for the cGMP (18)F-PET tracer manufacturing industry, and their

265 g coimmunoprecipitation and MS, we found the cGMP-AMP synthase (cGAS), an innate immune DNA sensor, t

266 anulosa cell volume, such that by 20 min the cGMP concentration in the follicle is uniformly low, app

267 Moreover, the cGMP-induced enhancement of LTP and memory was disrupted

268 An impairment of the cGMP pathway also may be involved in the pathogenesis of

269 ioning or pharmacological stimulation of the cGMP pathway and by using direct modulators of BK.

270 Inhibitors of the cGMP-degrading phosphodiesterase (PDE) 5 have achieved b

271 lyl cyclase activation and inhibition of the cGMP-degrading phosphodiesterase-5, ischemic preconditio

272 ion of cGMP and an increased activity of the cGMP-dependent protein kinase (protein kinase G, PKG) in

273 arning requires nuclear translocation of the cGMP-dependent protein kinase EGL-4 in AWC olfactory neu

274 Concordantly, inhibition of the cGMP-dependent protein kinase G (PKG) blocks egress indu

275 intracellular pool through inhibition of the cGMP-hydrolyzing enzyme phosphodiesterase type 5 (PDE5)

276 ulin secretion point to participation of the cGMP/PKG and cAMP/PKA/Epac (exchange protein directly ac

277 tibodies or APP knock-out mice, prevents the cGMP-dependent enhancement of LTP and memory.

278 ated that guanylate cyclase-1, producing the cGMP second messenger in photoreceptors, requires rhodop

279 Treatment with sildenafil, the cGMP derivative 8-bromoguanosine 3',5'-cyclic monophosph

280 gher than those of cGMP, suggesting that the cGMP-versus-cAMP selectivity of PKG is not controlled un

281 DA and D1R agonists, signaling through the cGMP/protein kinase G (PKG) pathway, suppressed cell via

282 AP1 is a GKAP, anchoring specifically to the cGMP-dependent protein kinase isoform Ibeta, and provide

283 It was shown that NPs, via their cGMP-forming guanylyl cyclase-A (GC-A) receptor and cGMP

284 aprinast, which we show acts in part through cGMP-dependent protein kinase (protein kinase G; PKG) to

285 cyte injury and prevents proteinuria through cGMP- and PKG-dependent binding of PPAR-gamma to the TRP

286 rent entering the cone outer segment through cGMP-gated (CNG) channels is carried in part by Ca(2+),

287 Signaling through cGMP has therapeutic potential in the colon, where it ha

288 le/particulate guanylate cyclase coupling to cGMP in cardiac dysautonomia.

289 cGMP/cAMP cross-talk and, in particular, to cGMP-driven augmentation of contractility in vitro and i

290 response to PSK but were fully responsive to cGMP, indicating that BAK1 acts in the PSK signal pathwa

291 response to PSK but are still responsive to cGMP, suggesting that cGMP acts downstream of PSKR1.

292 ing the C43S mutation was less responsive to cGMP-induced activation.

293 the conversion of guanosine triphosphate to cGMP.

294 Guanylyl cyclase-A (GC-A), the transmembrane cGMP-producing receptor shared by these peptides, is exp

295 Unexpectedly, cGMP-dependent protein kinase (PKG) inhibitor, but not g

296 h, supporting a role for PSKR1 signaling via cGMP in planta.

297 e in LTP mechanisms, here we studied whether cGMP affects Abeta levels and function during LTP.

298 ity of BRI1 is modulated by the kinase while cGMP, the product of the guanylate cyclase, in turn inhi

299 -dependent mechanism that is associated with cGMP production and is enhanced by acetazolamide and ral

300 e or Angeli's salt induced disulfides within cGMP-dependent protein kinase I-alpha (PKGIalpha), an in